Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 238 of the 265 references it cites were found in a registry or an index; 17 of the 323 sources its claims cite were checked for support.
Abstract
Objective: Our objective was to formulate a clinical practice guideline for the management of the pregnant woman with diabetes. Participants: The Task Force was composed of a chair, selected by the Clinical Guidelines Subcommittee of The Endocrine Society, 5 additional experts, a methodologist, and a medical writer. Evidence: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence. Consensus Process: One group meeting, several conference calls, and innumerable e-mail communications enabled consensus for all recommendations save one with a majority decision being employed for this single exception. Conclusions: Using an evidence-based approach, this Diabetes and Pregnancy Clinical Practice Guideline addresses important clinical issues in the contemporary management of women with type 1 or type 2 diabetes preconceptionally, during pregnancy, and in the postpartum setting and in the diagnosis and management of women with gestational diabetes during and after pregnancy.
Overview
CoChat Summary
TL;DR
This Endocrine Society clinical practice guideline provides evidence-based recommendations for managing type 1 or type 2 diabetes preconceptionally, during pregnancy, and postpartum, and for diagnosing and managing gestational diabetes. It uses GRADE and recommends universal early diabetes testing, 24–28 week 75-g OGTT with IADPSG criteria, tight glycemic targets, and lifestyle-first therapy with insulin or selected oral agents when needed.
Key findings
- Universal testing for overt diabetes is recommended at the first prenatal visit before 13 weeks (or as soon as possible thereafter) using fasting plasma glucose, HbA1c, or untimed random plasma glucose; overt diabetes thresholds are fasting ≥126 mg/dL (≥7.0 mmol/L), random ≥200 mg/dL (≥11.1 mmol/L), or HbA1c ≥6.5%, while early gestational diabetes is fasting 92–125 mg/dL (5.1–6.9 mmol/L).
- Gestational diabetes should be tested at 24–28 weeks with a 2-hour 75-g OGTT and diagnosed using IADPSG criteria: fasting 92–125 mg/dL (5.1–6.9 mmol/L), 1-hour ≥180 mg/dL (≥10.0 mmol/L), or 2-hour 153–199 mg/dL (8.5–11.0 mmol/L).
- Glycemic targets are preprandial ≤95 mg/dL (5.3 mmol/L), or ≤90 mg/dL (5.0 mmol/L) if safely achievable; 1-hour postmeal ≤140 mg/dL (7.8 mmol/L); 2-hour postmeal ≤120 mg/dL (6.7 mmol/L); and for overt diabetes HbA1c ≤7% (ideally ≤6.5%).
- Initial gestational diabetes treatment is medical nutrition therapy plus ≥30 minutes daily moderate exercise; pharmacotherapy is recommended if lifestyle is insufficient, with insulin preferred for diagnosis before 25 weeks or fasting plasma glucose >110 mg/dL (6.1 mmol/L), glyburide as a suitable alternative in other cases, and metformin restricted to women who refuse or cannot use insulin or glyburide and are not in the first trimester.
Methods
- The Endocrine Society appointed a Task Force composed of a chair, 5 additional experts, a methodologist, and a medical writer; it used the GRADE system to grade strength of recommendations and quality of evidence.
- The Task Force commissioned two systematic reviews and developed recommendations through one group meeting, several conference calls, and email communications; consensus was achieved for all recommendations except one, which used a majority decision.
- The commissioned reviews included a screening review of 39 original studies enrolling 87,830 women and a glucose-targets review of 34 original studies enrolling 9,433 women (15 randomized controlled trials, 18 cohort studies, and 1 case-control study).
Limitations
- Stated in the text: the quality of evidence for screening remains low because no randomized trials compared screening vs no screening and measured patient-important outcomes; the glucose-targets analysis could not control for maternal BMI and had significant heterogeneity, with sparse data for type 1 and type 2 diabetes and postprandial targets.
- Stated in the text: the recommendation to adopt IADPSG criteria was a majority opinion, not unanimous, and is acknowledged as arguable and controversial; implementation will substantially increase gestational diabetes diagnoses, medicalization of pregnancies, and healthcare costs.
- Evident from the text: many recommendations are ungraded or based on indirect evidence, unsystematic observations, or consensus; some key management recommendations rely on observational studies, and long-term safety data for metformin use in pregnancy are not yet available.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
10 Valid · 1 Not valid · 138 Not checked · 19 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Women with diabetes who receive preconception counseling have better preconception glycemic control (8, 9)”
§ Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 1.0 Preconception care of women with diabetes
What the sources say
- Not checked yetcites [8] Anwar A, Salih A, Masson E, Allen B, Wilkinson L, Lindow SW. The effect of pre-pregnancy counselling for women with pre-gestational diabetes on maternal health status. Eur J Obstet Gynecol Reprod Biol. 2011; 155: 137– 139. 21277071 source
- Partly supportedcites [9] Murphy HR, Roland JM, Skinner TC, et al. Effectiveness of a regional prepregnancy care program in women with type 1 and type 2 diabetes: Benefits beyond glycemic control. Diabetes Care. 2010; 33: 2514– 2520. 21115765 PMC2992180 sourceExperimental — accuracy not yet measured
The Results (Pregnancy preparation; page unavailable) report that women attending prepregnancy care were more likely to have received counseling and had significantly better glycemic control before pregnancy. The Methods (Maternal data; page unavailable) distinguish counseling from prepregnancy care, however, and the reported glycemic comparison is by care attendance, not counseling alone. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Maternal hyperglycemia in the first few weeks of pregnancy increases the risk of fetal malformations, spontaneous abortions, and perinatal mortality (14–18).”
§ Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 1.2. Evidence
What the sources say
- Supportedcites [14] Inkster ME, Fahey TP, Donnan PT, Leese GP, Mires GJ, Murphy DJ. Poor glycated haemoglobin control and adverse pregnancy outcomes in type 1 and type 2 diabetes: systematic review of observational studies. BMC Pregnancy Childbirth. 2006; 6: 30. 17074087 PMC1635059 source
The Background links inadequate glycaemic control around conception to increased congenital-abnormality risk, noting that organogenesis occurs early in pregnancy. The Discussion reports a greater than three-fold risk of congenital malformations with poor versus optimal glycaemic control. The paper describes this as an association, not proof of an exclusive causal effect. (LLM, conf=0.88)
- Not checked yetcites [15] Nielsen GL, Møller M, Sørensen HT. HbA1c in early diabetic pregnancy and pregnancy outcomes: a Danish population-based cohort study of 573 pregnancies in women with type 1 diabetes. Diabetes Care. 2006; 29: 2612– 2616. 17130193 source
- Supportedcites [16] Guerin A, Nisenbaum R, Ray JG. Use of maternal GHb concentration to estimate the risk of congenital anomalies in the offspring of women with prepregnancy diabetes. Diabetes Care. 2007; 30: 1920– 1925. 17446531 source
The introduction states that poor glycemic control in the periconception period is positively associated with congenital anomalies in offspring of women with prepregnancy diabetes. The Implications section adds that elevated periconceptional GHb heightens the risk of structural anomalies, supporting the claim in that population. (LLM, conf=0.91)
- Partly supportedcites [17] Suhonen L, Hiilesmaa V, Teramo K. Glycaemic control during early pregnancy and fetal malformations in women with type I diabetes. Diabetologia. 2000; 43: 79– 82. 10663219 sourceExperimental — accuracy not yet measured
The Abstract (p. 1) and Discussion (p. 3) report increased fetal-malformation risk with raised HbA1c in early pregnancy. The study concerns women with Type I diabetes and measures HbA1c before 14 weeks; it does not establish the risk specifically for the first few weeks or for pregnant women generally. (LLM, conf=0.84)
- Not checked yetcites [18] Bell R, Glinianaia SV, Tennant PW, Bilous RW, Rankin J. Peri-conception hyperglycaemia and nephropathy are associated with risk of congenital anomaly in women with pre-existing diabetes: a population-based cohort study. [published online ahead of print April 1, 2012]. Diabetologia. doi: 10.1007/s00125-012-2455-y. 22314812
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Rapid-acting insulin analogs are likely more able than regular human insulin to help a woman achieve postprandial blood glucose targets and are less likely to cause hypoglycemia; fetal outcomes, however, seem comparable (28–30).”
§ Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > Insulin therapy
What the sources say
- Not checked yetcites [28] Hod M, Damm P, Kaaja R, Visser GH, Dunne F, Demidova I, Hansen AS, Mersebach H; Insulin Aspart Pregnancy Study Group. Fetal and perinatal outcomes in type 1 diabetes pregnancy: a randomized study comparing insulin aspart with human insulin. Obstet Gynecol. 2008; 198: 186.e1– e7. 17905178
- Supportedcites [29] Mathiesen ER, Kinsley B, Amiel SA, et al; Insulin Aspart Pregnancy Study Group. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care. 2007; 30: 771– 776. 17392539 source
The Pregnancy outcome section (p. 5 of our copy) reports no significant between-treatment difference in live births (IAsp 87.3% vs HI 79.4%), fetal losses (8.9% vs 12.1%) or congenital malformations (4.3% vs 6.6%). The Discussion (Quality-of-life/overall text) states 'Safety profiles of IAsp and HI were comparable... pregnancy outcome was comparable between treatments,' and the Abstract concludes maternal safety profiles and pregnancy outcomes were similar between treatments. This directly supports the paraphrase that fetal outcomes with this rapid-acting analog appear comparable to regular human insulin. (LLM, conf=0.90)
- Not checked yetcites [30] Lapolla A, Dalfrà MG, Spezia R, et al. Outcome of pregnancy in type 1 diabetic patients treated with insulin lispro or regular insulin: an Italian experience. Acta Diabetol. 2008; 45: 61– 66. 18227964 source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Rapid-acting insulin analogs are likely more able than regular human insulin to help a woman achieve postprandial blood glucose targets and are less likely to cause hypoglycemia; fetal outcomes, however, seem comparable (28–30).”
§ Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > Insulin therapy
What the sources say
- Not checked yetcites [28] Hod M, Damm P, Kaaja R, Visser GH, Dunne F, Demidova I, Hansen AS, Mersebach H; Insulin Aspart Pregnancy Study Group. Fetal and perinatal outcomes in type 1 diabetes pregnancy: a randomized study comparing insulin aspart with human insulin. Obstet Gynecol. 2008; 198: 186.e1– e7. 17905178
- Partly supportedcites [29] Mathiesen ER, Kinsley B, Amiel SA, et al; Insulin Aspart Pregnancy Study Group. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care. 2007; 30: 771– 776. 17392539 sourceExperimental — accuracy not yet measured
The Hypoglycemic episodes section reports lower observed rates of major hypoglycemia with insulin aspart than with regular human insulin, but the estimated difference was not statistically significant. It also reports similar risks of all and minor hypoglycemia between treatments. Thus the study does not establish that rapid-acting insulin analogs generally are less likely to cause hypoglycemia. (LLM, conf=0.88)
- Not checked yetcites [30] Lapolla A, Dalfrà MG, Spezia R, et al. Outcome of pregnancy in type 1 diabetic patients treated with insulin lispro or regular insulin: an Italian experience. Acta Diabetol. 2008; 45: 61– 66. 18227964 source
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Untreated or insufficiently treated hypothyroidism reduces fertility and, in the event of pregnancy, increases the risk of miscarriage and impaired fetal brain development (64–68).”
§ Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > Insulin therapy
What the sources say
- Not checked yetcites [64] Casey BM, Dashe JS, Wells CE, et al. Subclinical hypothyroidism and pregnancy outcomes. Obstet Gynecol. 2005; 105: 239– 245. 15684146 source
- Not checked yetcites [65] Glinoer D, Soto MF, Bourdoux P, et al. Pregnancy in patients with mild thyroid abnormalities: maternal and neonatal repercussions. J Clin Endocrinol Metab. 1991; 73: 421– 427. 1906897 source
- Partly supportedcites [66] Haddow JE, Palomaki GE, Allan WC, et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med. 1999; 341: 549– 555. 10451459 sourceExperimental — accuracy not yet measured
Haddow et al. (1999) supports the untreated half of the claim: the Results (p. ~551) report that among the 62 women with thyroid deficiency, the 48 who were not treated during pregnancy had children whose full-scale WISC-III IQ averaged 7 points lower than the 124 matched controls (P=0.005), and the Discussion states that hypothyroidism in pregnant women 'can adversely affect their children's subsequent performance on neuropsychological tests,' even when mild/asymptomatic. However, the 'insufficiently treated' component is not supported and is arguably contrary to our copy: the Results state that 'the test scores of the children whose mothers were being treated (albeit inadequately) during pregnancy were similar to those of the control children in most categories,' and the Discussion concludes that treating maternal hypothyroidism 'appears to be beneficial for the child, even when treatment is inadequate as determined by measurements of thyrotropin.' The paper also frames its conclusion with hedging ('may adversely affect') and measures neuropsychological outcome in the children at 7-9 years rather than fetal brain development directly, so the citing sentence states at face value more than this source establishes. (LLM, conf=0.78)
- Not checked yetcites [67] Leung AS, Millar LK, Koonings PP, Montoro M, Mestman JH. Perinatal outcome in hypothyroid pregnancies. Obstet Gynecol. 1993; 81: 349– 353. 8437784 source
- Not checked yetcites [68] Man EB, Brown JF, Serunian SA. Maternal hypothyroxinemia: psychoneurological deficits of progeny. Ann Clin Lab Sci. 1991; 21: 227– 239. 1859163
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
129 more claims · 4 with their cited sources checked
Create a free account to see all 168 claims and to verify the 302 references still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 8
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Current guidelines emphasise that MNT should be delivered by a registered dietitian or a healthcare professional with specialised expertise in GDM [8].”
From Medical Nutrition Therapy for Women with Gestational Diabetes: Current Practice and Future Perspectives (2025) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The Endocrine Society recommends moderate energy restriction (1600 to 1800 kcal per day) or a 33% reduction in total calories for overweight/obese women with GDM to improve maternal glycaemia without compromising foetal growth or inducing ketosis [8].”
From Medical Nutrition Therapy for Women with Gestational Diabetes: Current Practice and Future Perspectives (2025) · cites this paper as [8]
Experimental — accuracy not yet measured
Citations
Cites
1 retracted
Committee Opinion No. 504: Screening and Diagnosis of Gestational Diabetes Mellitus
(2011) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3182310cc3 · Cited by 153 · cited 2×
“…although in agreement with the recommendations of the IADPSG and American Diabetes Association (56, 69), differs materially from the recommendation of other organizations including the American College of Obstetricians and Gynecologists (77) and the National Institutes of Health (78).”
RetractedDermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables
Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., Norris, S., Falck-Ytter, Y., Glasziou, P., & deBeer, H. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.04.026 · Cited by 10,681
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) group, an international group with expertise in development and implementation of evidence-based guidelines (2).”
Trumbo, P., Schlicker, S., Yates, A. A., & Poos, M. (2002) · Journal of the American Dietetic Association · doi:10.1016/s0002-8223(02)90346-9 · Cited by 5,993
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
International Association of Diabetes and Pregnancy Study Groups Consensus Panel (2010) · Diabetes Care · doi:10.2337/dc09-1848 · Cited by 5,390
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
Weight Gain During Pregnancy: Reexamining the Guidelines
Rasmussen, K. M., & Yaktine, A. L. (2009) · Cited by 4,473
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Effect of Treatment of Gestational Diabetes Mellitus on Pregnancy Outcomes
Crowther, C. A., Hiller, J. E., Moss, J. R., McPhee, A. J., Jeffries, W. S., & Robinson, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042973 · Cited by 3,159
Basevi, V., Di Mario, S., Morciano, C., Nonino, F., & Magrini, N. (2011) · Diabetes Care · doi:10.2337/dc11-0174 · Cited by 3,055
Haddow, J. E., Palomaki, G. E., Allan, W. C., Williams, J. R., Knight, G. J., Gagnon, J., O'Heir, C. E., Mitchell, M. L., Hermos, R. J., Waisbren, S. E., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908193410801 · Cited by 2,558
A Multicenter, Randomized Trial of Treatment for Mild Gestational Diabetes
Landon, M. B., Spong, C. Y., Thom, E., Carpenter, M. W., Ramin, S. M., Casey, B., Wapner, R. J., Varner, M. W., Rouse, D. J., Thorp, J. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902430 · Cited by 2,122
De Groot, L., Abalovich, M., Alexander, E. K., Amino, N., Barbour, L., Cobin, R. H., Eastman, C. J., Lazarus, J. H., Luton, D., Mandel, S. J., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2803 · Cited by 1,866
Self-citationMetformin versus insulin for the treatment of gestational diabetes
Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707193 · Cited by 1,291 · cited 1×
“Additionally, metformin-treated women with gestational diabetes have increased rates of preterm birth (89).”
Major congenital malformations after first-trimester exposure to ACE inhibitors
Cooper, W. O., Hernandez-Diaz, S., Arbogast, P. G., Dudley, J. A., Dyer, S., Gideon, P. S., Hall, K., & Ray, W. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055202 · Cited by 1,192 · cited 1×
“Evidence ACE inhibitors (51, 52) and angiotensin-receptor blockers (52, 53) are teratogenic (54).”
(1998) · PubMed · Cited by 992
Low–Glycemic Index Diets in the Management of Diabetes
Brand-Miller, J., Hayne, S., Petocz, P., & Colagiuri, S. (2003) · Diabetes Care · doi:10.2337/diacare.26.8.2261 · Cited by 951 · cited 1×
“Nonetheless, restricting the total amount of carbohydrate ingested may assist with glycemic control as may distributing carbohydrates over several meals and snacks, manipulating the types of carbohydrate consumed, and choosing low-glycemic-index foods (139, 140).”
A comparison of glyburide and insulin in women with gestational diabetes mellitus
Langer, O., Conway, D. L., Berkus, M. D., Xenakis, E. M.-J., & Gonzales, O. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431601 · Cited by 924 · cited 1×
“Glyburide is effective in controlling blood glucose in women with gestational diabetes and has been associated with favorable neonatal outcomes including the rate of large-for-gestational-age infants, macrosomia, neonatal intensive care unit admission, and neonatal hypoglycemia (90).”
American Diabetes Association (2004) · Diabetes Care · doi:10.2337/diacare.27.2007.s88 · Cited by 916
Subclinical hypothyroidism and pregnancy outcomes
Casey, B. M., Dashe, J. S., Wells, C. E., McIntire, D. D., Byrd, W., Leveno, K. J., & Cunningham, F. G. (2005) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000152345.99421.22 · Cited by 903
Weiss, P. (1988) · Cited by 780
Kurtzhals, P., Schäffer, L., Sørensen, A., Kristensen, C., Jonassen, I., Schmid, C., & Trüb, T. (2000) · Diabetes · doi:10.2337/diabetes.49.6.999 · Cited by 739 · cited 1×
“Of the two available long-acting insulin analogs, det-emir has a theoretical advantage over glargine during pregnancy because glargine’s much higher affinity for the IGF-1 receptor (150) raises concerns about increased mitogenic activity (150–152).”
Correlations between Antepartum Maternal Metabolism and Intelligence of Offspring
Rizzo, T., Metzger, B. E., Burns, W. J., & Burns, K. (1991) · New England Journal of Medicine · doi:10.1056/nejm199109263251303 · Cited by 707
Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study
The HAPO Study Cooperative Research Group (2009) · Diabetes · doi:10.2337/db08-1112 · Cited by 702
Effect of body mass index on pregnancy outcomes in nulliparous women delivering singleton babies
Bhattacharya, S., Campbell, D. M., Liston, W. A., & Bhattacharya, S. (2007) · BMC Public Health · doi:10.1186/1471-2458-7-168 · Cited by 688
The prevalence and impact of overweight and obesity in an Australian obstetric population
Callaway, L. K., Chang, A. M., McIntyre, H. D., & Prins, J. B. (2006) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2006.tb00115.x · Cited by 634
Sermer, M., Naylor, C. D., Gare, D. J., Kenshole, A. B., Ritchie, J. W. K., Farine, D., Cohen, H. R., McArthur, K., Holzapfel, S., Biringer, A., et al. (1995) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(95)90183-3 · Cited by 510
Hyperglycemia and Adverse Pregnancy Outcomes: The HAPO Study Cooperative Research Group
(2008) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0b013e318187b7a2 · Cited by 488
Perinatal outcome in hypothyroid pregnancies
Leung, A. S., Millar, L. K., Koonings, P. P., Montoro, M., & Mestman, J. H. (1993) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(93)90343-u · Cited by 475
Self-citationOwen, C. G., Martin, R. M., Whincup, P. H., Smith, G. D., & Cook, D. G. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/84.5.1043 · Cited by 467
Ratner, R. E., Hirsch, I. B., Neifing, J. L., Garg, S. K., Mecca, T. E., & Wilson, C. A. (2000) · Diabetes Care · doi:10.2337/diacare.23.5.639 · Cited by 455 · cited 1×
“Compared with NPH insulin, use of the long-acting insulin analogs insulin detemir or insulin glargine is associated with lower rates of nocturnal hypoglycemia (31, 32).”
Ray, J. G. (2001) · QJM · doi:10.1093/qjmed/94.8.435 · Cited by 430 · cited 1×
“Evidence Women with diabetes who receive preconception counseling have better preconception glycemic control (8, 9) and are more likely to have favorable pregnancy outcomes, including lower rates of congenital anomalies (9, 10) and spontaneous abortions (11, 12).”
Godsland, I. F., Crook, D., Simpson, R., Proudler, T., Felton, C., Lees, B., Anyaoku, V., Devenport, M., & Wynn, V. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011153232003 · Cited by 417 · cited 1×
“Progestinonly oral contraceptives do not affect blood glucose values or BP in women with type 1 diabetes (231, 232); however, there is some limited evidence that these medications increase the risk for later developing type 2 diabetes in women who have had gestational diabetes (222, 233).”
Maternal postprandial glucose levels and infant birth weight: the diabetes in early pregnancy study
Jovanovic-Peterson, L., Peterson, C. M., Reed, G. F., Metzger, B. E., Mills, J. L., Knopp, R. H., & Aarons, J. H. (1991) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(91)90637-7 · Cited by 411 · cited 1×
“Nonetheless, restricting the total amount of carbohydrate ingested may assist with glycemic control as may distributing carbohydrates over several meals and snacks, manipulating the types of carbohydrate consumed, and choosing low-glycemic-index foods (139, 140).”
Misso, M. L., Egberts, K. J., Page, M., O'Connor, D., & Shaw, J. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005103.pub2 · Cited by 406
(1998) · PubMed · Cited by 404
Metabolic Control and Progression of Retinopathy: The Diabetes in Early Pregnancy Study
Chew, E. Y., Mills, J. L., Metzger, B. E., Remaley, N. A., Jovanovic-Peterson, L., Knopp, R. H., Conley, M., Rand, L., Simpson, J. L., Holmes, L. B., et al. (1995) · Diabetes Care · doi:10.2337/diacare.18.5.631 · Cited by 402 · cited 2×
“The absence of retinopathy before conception confers very small risk of development of significant retinopathy during pregnancy; nonetheless, significant retinopathy can develop and progress during pregnancy, even if not identified preconceptionally (40).”
Diabetes Control and Complications Trial Research Group (2000) · Diabetes Care · doi:10.2337/diacare.23.8.1084 · Cited by 385
Acute myocardial infarction associated with pregnancy
Roth, A., & Elkayam, U. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.03.049 · Cited by 381
Pregnancy in patients with mild thyroid abnormalities: maternal and neonatal repercussions
GLINOER, D., SOTO, M. F., BOURDOUX, P., LEJEUNE, B., DELANGE, F., LEMONE, M., KINTHAERT, J., ROBIJN, C., GRUN, J.-P., & NAYER, P. D. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-2-421 · Cited by 379
Hermansen, K., Fontaine, P., Kukolja, K. K., Peterkova, V., Leth, G., & Gall, M.-A. (2004) · Diabetologia · doi:10.1007/s00125-004-1365-z · Cited by 365
The effect of gestational weight gain by body mass index on maternal and neonatal outcomes
Crane, J. M. G., White, J., Murphy, P., Burrage, L., & Hutchens, D. (2009) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(16)34050-6 · Cited by 363
Breastfeeding and incidence of non-insulin-dependent diabetes mellitus in Pima Indians
Pettitt, D. J., Forman, M. R., Hanson, R. L., Knowler, W. C., & Bennett, P. H. (1997) · The Lancet · doi:10.1016/s0140-6736(96)12103-6 · Cited by 357
Kjos, S. L., Peters, R. K., Xiang, A., Henry, O. A., Montoro, M., & Buchanan, T. A. (1995) · Diabetes · doi:10.2337/diab.44.5.586 · Cited by 356
Bullo, M., Tschumi, S., Bucher, B. S., Bianchetti, M. G., & Simonetti, G. D. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.196352 · Cited by 334 · cited 2×
“This is most proven for use of these drugs during the second and third trimesters (54).”
O'Sullivan, J. B. (1991) · Diabetes · doi:10.2337/diab.40.2.s131 · Cited by 332
Maternal postprandial glucose levels and infant birth weight: The Diabetes in Early Pregnancy Study
Jovanovic‐Peterson, L., Peterson, C., Reed, G., Metzger, B., Mills, J., Knopp, R., & Aarons, J. (1991) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(91)90499-u · Cited by 322
Suhonen, L., Hiilesmaa, V., & Teramo, K. (2000) · Diabetologia · doi:10.1007/s001250050010 · Cited by 302
Swiglo, B. A., Murad, M. H., Schünemann, H. J., Kunz, R., Vigersky, R. A., Guyatt, G. H., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1907 · Cited by 302 · cited 1×
“A detailed description of the grading scheme has been published elsewhere (3).”
Self-citationBaillargeon, J.-P., Jakubowicz, D. J., Iuorno, M. J., Jakubowicz, S., & Nestler, J. E. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.02.127 · Cited by 300
Vague, P., Selam, J.-L., Skeie, S., De Leeuw, I., Elte, J. W. F., Haahr, H., Kristensen, A., & Draeger, E. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.590 · Cited by 294
FRANZ, M. J., MONK, A., BARRY, B., McCLAIN, K., WEAVER, T., COOPER, N., UPHAM, P., BERGENSTAL, R., & MAZZE, R. S. (1995) · Journal of the American Dietetic Association · doi:10.1016/s0002-8223(95)00276-6 · Cited by 289
Wilson, R. D., Wilson, R. D., Désilets, V., Wyatt, P., Langlois, S., Gagnon, A., Allen, V., Blight, C., Johnson, J.-A., Audibert, F., et al. (2007) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(16)32685-8 · Cited by 288 · cited 3×
“Taking a daily folic acid supplement preconceptionally reduces the risk of neural tube defects (38).”
Lauenborg, J., Mathiesen, E., Hansen, T., Glümer, C., Jørgensen, T., Borch-Johnsen, K., Hornnes, P., Pedersen, O., & Damm, P. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1713 · Cited by 279
Pettitt, D. J., Knowler, W. C., Baird, H. R., & Bennett, P. H. (1980) · Diabetes Care · doi:10.2337/diacare.3.3.458 · Cited by 278
Pregnancy outcomes in the Diabetes Control and Complications Trial
(1996) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(96)70683-x · Cited by 278 · cited 1×
“Maternal hypoglycemia has not been proven to be deleterious to the fetus and in particular has not been found to be associated with an increased risk of congenital anomalies (27).”
Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis
Gilbert, C., Valois, M., & Koren, G. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.02.098 · Cited by 274
Maternal Glycemic Control and Hypoglycemia in Type 1 Diabetic Pregnancy
Mathiesen, E. R., Kinsley, B., Amiel, S. A., Heller, S., McCance, D., Duran, S., Bellaire, S., Raben, A., & on behalf of the Insulin Aspart Pregnancy Study Group (2007) · Diabetes Care · doi:10.2337/dc06-1887 · Cited by 265
Increasing Incidence of Diabetes After Gestational Diabetes
Lauenborg, J., Hansen, T., Jensen, D. M., Vestergaard, H., Mølsted-Pedersen, L., Hornnes, P., Locht, H., Pedersen, O., & Damm, P. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1194 · Cited by 257
’Accelerated starvation’ and the skipped breakfast in late normal pregnancy
Metzger, B., Vileisis, R., Ravnikar, V., & Freinkel, N. (1982) · The Lancet · doi:10.1016/s0140-6736(82)91750-0 · Cited by 256
Hebert, M., Ma, X., Naraharisetti, S., Krudys, K., Umans, J., Hankins, G., Caritis, S., Miodovnik, M., Mattison, D., Unadkat, J., et al. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.5 · Cited by 252 · cited 1×
“Evidence In pregnant women taking glyburide, the umbilical cord glyburide concentration is undetectable (90, 173– 176) or, at most, very low (177).”
Gunderson, E. P., Murtaugh, M. A., Lewis, C. E., Quesenberry, C. P., West, D. S., & Sidney, S. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802551 · Cited by 252
(1998) · PubMed · Cited by 239
Predictors of postpartum diabetes in women with gestational diabetes mellitus
Löbner, K., Knopff, A., Baumgarten, A., Mollenhauer, U., Marienfeld, S., Garrido-Franco, M., Bonifacio, E., & Ziegler, A.-G. (2006) · Diabetes · doi:10.2337/diabetes.55.03.06.db05-0746 · Cited by 234
Inkster, M. E., Fahey, T. P., Donnan, P. T., Leese, G. P., Mires, G. J., & Murphy, D. J. (2006) · BMC Pregnancy and Childbirth · doi:10.1186/1471-2393-6-30 · Cited by 233
Jensen, D. M., Korsholm, L., Ovesen, P., Beck-Nielsen, H., Moelsted-Pedersen, L., Westergaard, J. G., Moeller, M., & Damm, P. (2009) · Diabetes Care · doi:10.2337/dc08-2061 · Cited by 227 · cited 1×
“however, also been reported (20) that there is a stable”
Type 2 Diabetes Mellitus in Children: Prenatal and Early Infancy Risk Factors Among Native Canadians
Young, T. K., Martens, P. J., Taback, S. P., Sellers, E. A. C., Dean, H. J., Cheang, M., & Flett, B. (2002) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.156.7.651 · Cited by 227
Pregnancy outcome in type 1 diabetic women with microalbuminuria
Ekbom, P., Damm, P., Feldt-Rasmussen, B., Feldt-Rasmussen, U., Mølvig, J., & Mathiesen, E. R. (2001) · Diabetes Care · doi:10.2337/diacare.24.10.1739 · Cited by 224 · cited 1×
“Mild preconceptional renal dysfunction manifesting only as microalbuminuria may worsen during pregnancy with greater amounts of proteinuria (47); however, the degree of worsening is typically both modest and reversible once pregnancy is completed so long as BP and blood glucose remain well controlled during the pregna…”
Bell, R., Glinianaia, S. V., Tennant, P. W. G., Bilous, R. W., & Rankin, J. (2012) · Diabetologia · doi:10.1007/s00125-012-2455-y · Cited by 224 · cited 2×
“It has been reported (16, 18) that the risk progressively rises in concert with the degree of periconceptional HbA1C elevation, although an increased risk compared with the general childbearing population has been observed with an HbA1C as low as 6.4% (18).”
InfluentialPlagemann, A., Harder, T., Franke, K., & Kohlhoff, R. (2002) · Diabetes Care · doi:10.2337/diacare.25.1.16 · Cited by 223
Sibai, B. M., Caritis, S., Hauth, J., Lindheimer, M., VanDorsten, J. P., MacPherson, C., Klebanoff, M., Landon, M., Miodovnik, M., Paul, R., et al. (2000) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(00)70225-0 · Cited by 222
Jovanovic-Peterson, L., Durak, E. P., & Peterson, C. M. (1989) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(89)90534-6 · Cited by 220 · cited 1×
“exercise (83–86) and non–weight-bearing exercise (87)”
Mathiesen, E. R., Hod, M., Ivanisevic, M., Duran Garcia, S., Brøndsted, L., Jovanovič, L., Damm, P., McCance, D. R., & on behalf of the Detemir in Pregnancy Study Group (2012) · Diabetes Care · doi:10.2337/dc11-2264 · Cited by 219
Self-citationThyroid Dysfunction in Patients With Type 1 Diabetes
Umpierrez, G. E., Latif, K. A., Murphy, M. B., Lambeth, H. C., Stentz, F., Bush, A., & Kitabchi, A. E. (2003) · Diabetes Care · doi:10.2337/diacare.26.4.1181 · Cited by 215
Guerin, A., Nisenbaum, R., & Ray, J. G. (2007) · Diabetes Care · doi:10.2337/dc07-0278 · Cited by 215
Breast-Feeding and Risk for Childhood Obesity
Mayer-Davis, E. J., Rifas-Shiman, S. L., Zhou, L., Hu, F. B., Colditz, G. A., & Gillman, M. W. (2006) · Diabetes Care · doi:10.2337/dc06-0974 · Cited by 212
Population pharmacokinetics of metformin in late pregnancy
Charles, B., Norris, R., Xiao, X., & Hague, W. (2006) · Therapeutic Drug Monitoring · doi:10.1097/01.ftd.0000184161.52573.0e · Cited by 212
Toward universal criteria for gestational diabetes: the 75-gram glucose tolerance test in pregnancy
Sacks, D. A., Greenspoon, J. S., Abu-Fadil, S., Henry, H. M., Wolde-Tsadik, G., & Yao, J. F. F. (1995) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(95)90580-4 · Cited by 210
Pharmacokinetics of metformin during pregnancy
Eyal, S., Easterling, T. R., Carr, D., Umans, J. G., Miodovnik, M., Hankins, G. D. V., Clark, S. M., Risler, L., Wang, J., Kelly, E. J., et al. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.031245 · Cited by 209
Edison, R. J., & Muenke, M. (2004) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.30386 · Cited by 206
Hypoglycemia in Pregnant Women With Type 1 Diabetes
Nielsen, L. R., Pedersen-Bjergaard, U., Thorsteinsson, B., Johansen, M., Damm, P., & Mathiesen, E. R. (2008) · Diabetes Care · doi:10.2337/dc07-1066 · Cited by 204
Quan, A. (2006) · Early Human Development · doi:10.1016/j.earlhumdev.2005.11.001 · Cited by 200 · cited 1×
“Evidence ACE inhibitors (51, 52) and angiotensin-receptor blockers (52, 53) are teratogenic (54).”
Russell-Jones, D., Simpson, R., Hylleberg, B., Draeger, E., & Bolinder, J. (2004) · Clinical Therapeutics · doi:10.1016/s0149-2918(04)90072-0 · Cited by 194
Buchanan, T. A., Kjos, S. L., Montoro, M. N., Wu, P. Y. K., Madrilejo, N. G., Gonzalez, M., Nunez, V., Pantoja, P. M., & Xiang, A. (1994) · Diabetes Care · doi:10.2337/diacare.17.4.275 · Cited by 186
Effectiveness of a Regional Prepregnancy Care Program in Women With Type 1 and Type 2 Diabetes
Murphy, H. R., Roland, J. M., Skinner, T. C., Simmons, D., Gurnell, E., Morrish, N. J., Soo, S.-C., Kelly, S., Lim, B., Randall, J., et al. (2010) · Diabetes Care · doi:10.2337/dc10-1113 · Cited by 186
Kjos, S. L., Schaefer-Graf, U., Sardesi, S., Peters, R. K., Buley, A., Xiang, A. H., Bryne, J. D., Sutherland, C., Montoro, M. N., & Buchanan, T. A. (2001) · Diabetes Care · doi:10.2337/diacare.24.11.1904 · Cited by 180 · cited 1×
“There are some data to suggest that increased fetal abdominal circumference, as detected on ultrasound, may be used to help determine whether insulin should be introduced in women with gestational diabetes (112, 113).”
Jacobson, G. F., Ramos, G. A., Ching, J. Y., Kirby, R. S., Ferrara, A., & Field, D. R. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2005.03.018 · Cited by 177
Hod, M., Damm, P., Kaaja, R., Visser, G. H. A., Dunne, F., Demidova, I., Hansen, A.-S. P., & Mersebach, H. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2007.08.005 · Cited by 176
The Potential Diabetic and Her Treatment in Pregnancy
(2003) · Obstetrics & Gynecology · doi:10.1097/00006250-200307000-00004 · Cited by 175 · cited 1×
“Blood glucose-lowering pharmacological therapy is effective at improving outcomes in women with gestational diabetes whose hyperglycemia does not respond sufficiently to lifestyle therapy (71, 82, 88–90).”
Kjos, S. L. (1998) · JAMA · doi:10.1001/jama.280.6.533 · Cited by 174 · cited 1×
“Progestinonly oral contraceptives do not affect blood glucose values or BP in women with type 1 diabetes (231, 232); however, there is some limited evidence that these medications increase the risk for later developing type 2 diabetes in women who have had gestational diabetes (222, 233).”
Kim, C.-H., Ahn, J.-W., Kang, S. P., Kim, S.-H., Chae, H.-D., & Kang, B.-M. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2010.12.004 · Cited by 172 · cited 1×
“Progestinonly oral contraceptives do not affect blood glucose values or BP in women with type 1 diabetes (231, 232); however, there is some limited evidence that these medications increase the risk for later developing type 2 diabetes in women who have had gestational diabetes (222, 233).”
Progression of diabetic retinopathy in pregnancy: association with hypertension in pregnancy
Rosenn, B., Miodovnik, M., Kranias, G., Khoury, J., Combs, C. A., Mimouni, F., Siddiqi, T. A., & Lipman, M. J. (1992) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(11)90608-5 · Cited by 169 · cited 1×
“Additional risk factors for progression of retinopathy during pregnancy include preexisting hypertension (43), poorly controlled hypertension during pregnancy (44), preeclampsia (45), and poor glycemic control at the onset of and during pregnancy (41).”
Alvarez-Marfany, M., Roman, S. H., Drexler, A. J., Robertson, C., & Stagnaro-Green, A. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.79.1.8027213 · Cited by 167
Schaefer-Graf, U. M., Buchanan, T. A., Xiang, A. H., Peters, R. K., & Kjos, S. L. (2002) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2002.121895 · Cited by 162
ROSENN, B., MIODOVNIK, M., HOLCBERG, G., KHOURY, J., & SIDDIQI, T. (1995) · Obstetrics & Gynecology · doi:10.1016/0029-7844(94)00415-a · Cited by 161
Early postpartum metabolic assessment in women with prior gestational diabetes
Pallardo, F., Herranz, L., Garcia-Ingelmo, T., Grande, C., Martin-Vaquero, P., Jañez, M., & Gonzalez, A. (1999) · Diabetes Care · doi:10.2337/diacare.22.7.1053 · Cited by 160
Bartley, P. C., Bogoev, M., Larsen, J., & Philotheou, A. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02407.x · Cited by 159
KULKARNI, K., CASTLE, G., GREGORY, R., HOLMES, A., LEONTOS, C., POWERS, M., SNETSELAAR, L., SPLETT, P., & WYLIE-ROSETT, J. (1998) · Journal of the American Dietetic Association · doi:10.1016/s0002-8223(98)00017-0 · Cited by 158
Ferrara, A. M., Weiss, N. S., Hedderson, M. M., Quesenberry, C. P., Selby, J. V., Ergas, I. J., Peng, T., Escobar, G. J., Pettitt, D. J., & Sacks, D. A. (2006) · Diabetologia · doi:10.1007/s00125-006-0517-8 · Cited by 155 · cited 1×
“The Hyperglycemia andAdversePregnancyOutcomestudy(6)andotherstud-ies (72–76) have confirmed continuous graded relationships between higher maternal glucose and increasing frequency of birth weight above the 90th percentile, primary cesarean section, neonatal hypoglycemia, and elevated cord…”
Mukhopadhyay, A., Farrell, T., Fraser, R. B., & Ola, B. (2007) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2007.03.062 · Cited by 153 · cited 1×
“167) glycemic control and pregnancy outcomes (168, 169)”
Evers, I. M., ter Braak, E. W. M. T., de Valk, H. W., van der Schoot, B., Janssen, N., & Visser, G. H. A. (2002) · Diabetes Care · doi:10.2337/diacare.25.3.554 · Cited by 152
Reader, D., Splett, P. L., & Gunderson, E. P. (2006) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2006.06.009 · Cited by 152 · cited 1×
“Nevertheless, nutrition therapy has been shown to improve glycemic control for people living with overt diabetes (119, 120) and for women with gestational diabetes (121).”
Natural course of gestational diabetes mellitus: long term follow up of women in the SPAWN study
Linné, Y. (2002) · BJOG: An International Journal of Obstetrics and Gynaecology · doi:10.1016/s1470-0328(02)01973-0 · Cited by 148
Dhulkotia, J. S., Ola, B., Fraser, R., & Farrell, T. (2010) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2010.06.044 · Cited by 145
Järvelä, I. Y., Juutinen, J., Koskela, P., Hartikainen, A.-L., Kulmala, P., Knip, M., & Tapanainen, J. S. (2006) · Diabetes Care · doi:10.2337/diacare.29.03.06.dc05-1118 · Cited by 145
Early Introduction of Dairy Products Associated with Increased Risk of IDDM in Finnish Children
Virtanen, S. M., Räsänen, L., Ylönen, K., Aro, A., Clayton, D., Langholz, B., Pitkäniemi, J., Savilahti, E., Lounamaa, R., Tuomilehto, J., et al. (1993) · Diabetes · doi:10.2337/diab.42.12.1786 · Cited by 144
HbA1c in Early Diabetic Pregnancy and Pregnancy Outcomes
Nielsen, G. L., Møller, M., & Sørensen, H. T. (2006) · Diabetes Care · doi:10.2337/dc06-0914 · Cited by 140
Tennant, P. W. G., Rankin, J., & Bell, R. (2011) · Human Reproduction · doi:10.1093/humrep/der052 · Cited by 134
Jovanovic, L., Metzger, B. E., Knopp, R. H., conley, M. R., Park, E., Lee, Y. J., Simpson, J. L., Holmes, L., Aarons, J. H., & Mills, J. L. (1998) · Diabetes Care · doi:10.2337/diacare.21.11.1978 · Cited by 129
Glyburide for the treatment of gestational diabetes
Kremer, C. J., & Duff, P. (2004) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.02.032 · Cited by 126
Perinatal outcome and long-term follow-up associated with modern management of diabetic nephropathy
Gordon, M. (1996) · Obstetrics & Gynecology · doi:10.1016/0029-7844(95)00420-3 · Cited by 125
(2013) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e31829c3e64 · Cited by 124
Pregnancy-induced sight-threatening diabetic retinopathy in women with type 1 diabetes
Vestgaard, M., Ringholm, L., Laugesen, C. S., Rasmussen, K. L., Damm, P., & Mathiesen, E. R. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.02958.x · Cited by 121 · cited 1×
“Additional risk factors for progression of retinopathy during pregnancy include preexisting hypertension (43), poorly controlled hypertension during pregnancy (44), preeclampsia (45), and poor glycemic control at the onset of and during pregnancy (41).”
(1991) · PubMed · Cited by 121
Chmait, R., Dinise, T., & Moore, T. (2004) · Journal of Perinatology · doi:10.1038/sj.jp.7211147 · Cited by 118 · cited 2×
“Compared with insulin, glyburide may be more convenient, is less expensive (184), does not require intensive educational instruction at initiation of therapy, and is preferred by most patients (179, 183).”
Motherisk Rounds: Risks of Statin Use During Pregnancy: A Systematic Review
Kazmin, A., Garcia-Bournissen, F., & Koren, G. (2007) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(16)32656-1 · Cited by 117
Maternal Glucose at 28 Weeks of Gestation Is Not Associated With Obesity in 2-Year-Old Offspring
Pettitt, D. J., McKenna, S., McLaughlin, C., Patterson, C. C., Hadden, D. R., & McCance, D. R. (2010) · Diabetes Care · doi:10.2337/dc09-2384 · Cited by 116
Self-citationMetformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome
Glueck, C. J., Bornovali, S., Pranikoff, J., Goldenberg, N., Dharashivkar, S., & Wang, P. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01251.x · Cited by 115
Insulin lispro and regular insulin in pregnancy
Bhattacharyya, A. (2001) · QJM · doi:10.1093/qjmed/94.5.255 · Cited by 114
American Diabetes Association (1998) · Diabetes Care · doi:10.2337/diacare.21.1.s60 · Cited by 114
Use of glyburide for the treatment of gestational diabetes: the San Antonio experience
Conway, D. L., Gonzales, O., & Skiver, D. (2004) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767050310001650725 · Cited by 112
(1985) · Diabetes · doi:10.2337/diab.34.2.s123 · Cited by 106
Insulin Glargine Safety in Pregnancy
Pollex, E. K., Feig, D. S., Lubetsky, A., Yip, P. M., & Koren, G. (2010) · Diabetes Care · doi:10.2337/dc09-1045 · Cited by 104
Long-Range Implications for the Mother: The Aberdeen Experience
Stowers, J. M., Sutherland, H. W., & Kerridge, D. F. (1985) · Diabetes · doi:10.2337/diab.34.2.s106 · Cited by 104
Wyatt, J. W., Frias, J. L., Hoyme, H. E., Jovanovic, L., Kaaja, R., Brown, F., Garg, S., Lee‐Parritz, A., Seely, E. W., Kerr, L., et al. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01498.x · Cited by 103 · cited 1×
“Rapid-acting insulin does not increase the risk of teratogenicity (30, 157, 158, 163–165).”
Self-citationInsulin lispro therapy in pregnancies complicated by type 1 diabetes mellitus
Persson, B., Swahn, M.-L., Hjertberg, R., Hanson, U., Nord, E., Nordlander, E., & Hansson, L.-O. (2002) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(02)00141-9 · Cited by 103
Chen, R., Yogev, Y., Ben-Haroush, A., Jovanovic, L., Hod, M., & Phillip, M. (2003) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/jmf.14.4.256.260 · Cited by 101
Self-citationMetabolic effects of 1200-kcal diet in obese pregnant women with gestational diabetes
Magee, M. S., Knopp, R. H., & Benedetti, T. J. (1990) · Diabetes · doi:10.2337/diab.39.2.234 · Cited by 101
Lain, K. Y., Garabedian, M. J., Daftary, A., & Jeyabalan, A. (2009) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2009.02.038 · Cited by 100 · cited 1×
“Although some evidence does exist of higher rates of macrosomia and largefor-gestational-age infants (176) in pregnant women taking glyburide compared with women taking insulin, neonates had similar body composition, measures of glycemic control, and cord metabolic biomarkers.”
Hypocaloric diets and ketogenesis in the management of obese gestational diabetic women
Knopp, R. H., Magee, M. S., Raisys, V, Benedetti, T., & Bonet, B. (1991) · Journal of the American College of Nutrition · doi:10.1080/07315724.1991.10718184 · Cited by 97
Dietary advice in pregnancy for preventing gestational diabetes mellitus
Tieu, J., Crowther, C. A., & Middleton, P. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006674.pub2 · Cited by 95 · cited 1×
“Evidence There is no definitive evidence for the optimal proportion of carbohydrate in the diet of women with overt or gestational diabetes; values from 40% to 45% of energy intake (137) to 60% (if the carbohydrate is from complex sources) (138) have been recommended.”
JENSEN, D. M., Korsholm, L., Ovesen, P., Beck‐Nielsen, H., Mølsted‐Pedersen, L., & Damm, P. (2007) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1080/00016340701823975 · Cited by 94
Pre‐conception management of insulin‐dependent diabetes: Improvement of pregnancy outcome
Rosenn, B., Miodovnik, M., Combs, C., Khoury, J., & Siddiqi, T. (1992) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(92)90749-9 · Cited by 94 · cited 1×
“Evidence Women with diabetes who receive preconception counseling have better preconception glycemic control (8, 9) and are more likely to have favorable pregnancy outcomes, including lower rates of congenital anomalies (9, 10) and spontaneous abortions (11, 12).”
Use of insulin glargine during pregnancy: a case-control pilot study
Price, N., Bartlett, C., & Gillmer, M. (2007) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2006.01216.x · Cited by 93
Gestational diabetes mellitus and subsequent development of overt diabetes mellitus.
Damm, P. (1998) · PubMed · Cited by 92
Predictive factors of developing diabetes mellitus in women with gestational diabetes
ÅBerg, A. E. B., Jönsson, E. K., Eskilsson, I., Landin‐Olsson, M., & Frid, A. H. (2002) · Acta Obstetricia et Gynecologica Scandinavica · doi:10.1046/j.0001-6349.2001.00000.x · Cited by 90
Schaefer-Graf, U. M., Hartmann, R., Pawliczak, J., Passow, D., Abou-Dakn, M., Vetter, K., & Kordonouri, O. (2006) · Diabetes Care · doi:10.2337/dc05-2413 · Cited by 89
Thrailkill, K. M., Quattrin, T., Baker, L., Kuntze, J. E., Compton, P. G., & Martha, P. M. (1999) · Diabetes Care · doi:10.2337/diacare.22.4.585 · Cited by 88
Predictors of glyburide failure in the treatment of gestational diabetes
Kahn, B. F., Davies, J. K., Lynch, A. M., Reynolds, R. M., & Barbour, L. A. (2006) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000218704.28313.36 · Cited by 85
Acute effect of exercise on blood glucose and insulin levels in women with gestational diabetes
Avery, M. D., & Walker, A. J. (2001) · Journal of Maternal-Fetal and Neonatal Medicine · doi:10.1080/jmf.10.1.52.58-4 · Cited by 85
Metformin Versus Insulin for the Treatment of Gestational Diabetes
Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P. (2009) · Obstetric Anesthesia Digest · doi:10.1097/01.aoa.0000344705.95925.07 · Cited by 85
Rodekamp, E., Harder, T., Kohlhoff, R., Franke, K., Dudenhausen, J. W., & Plagemann, A. (2005) · Diabetes Care · doi:10.2337/diacare.28.6.1457 · Cited by 84
SKOUBY, S. O., ANDERSEN, O., SAURBREY, N., & KÜHL, C. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-64-3-519 · Cited by 83 · cited 1×
“Combined oral contraceptive use by women with a history of gestational diabetes does not increase the risk of later developing type 2 diabetes (220–223).”
(1994) · PubMed · Cited by 83
The role of continuous glucose monitoring in clinical decision-making in diabetes in pregnancy
McLACHLAN, K., JENKINS, A., & O’NEAL, D. (2007) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/j.1479-828x.2007.00716.x · Cited by 82
Rochon, M., Rand, L., Roth, L., & Gaddipati, S. (2006) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2006.07.029 · Cited by 82 · cited 1×
“1 mmol/L) on a 100-g OGTT (179) or 50-g glucose challenge (180, 181), have had their gestational diabetes detected before 25 weeks gestation (182), have glyburide initiated after 30 weeks, have fasting plasma glucose 110 mg/dL (6.”
Chen, R., Ben-Haroush, A., Weissmann-Brenner, A., Melamed, N., Hod, M., & Yogev, Y. (2007) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2007.06.007 · Cited by 81 · cited 1×
“poglycemia has, however, been reported (172).”
Self-citationTransfer of glyburide and glipizide into breast milk
Feig, D. S., Briggs, G. G., Kraemer, J. M., Ambrose, P. J., Moskovitz, D. N., Nageotte, M., Donat, D. J., Padilla, G., Wan, S., Klein, J., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.8.1851 · Cited by 81
Progression of retinopathy during pregnancy in type 1 diabetic women treated with insulin lispro
Loukovaara, S., Immonen, I., Teramo, K. A., & Kaaja, R. (2003) · Diabetes Care · doi:10.2337/diacare.26.4.1193 · Cited by 80 · cited 1×
“dial blood glucose control (157) and HbA1C reduction”
(2003) · PubMed · Cited by 79
Hypertensive disorders of pregnancy in women with type 1 and type 2 diabetes
Cundy, T., Slee, F., Gamble, G., & Neale, L. (2002) · Diabetic Medicine · doi:10.1046/j.1464-5491.2002.00729.x · Cited by 79 · cited 1×
“Additional risk factors for progression of retinopathy during pregnancy include preexisting hypertension (43), poorly controlled hypertension during pregnancy (44), preeclampsia (45), and poor glycemic control at the onset of and during pregnancy (41).”
Hofmann, T., Horstmann, G., & Stammberger, I. (2002) · International Journal of Toxicology · doi:10.1080/10915810290096315 · Cited by 77 · cited 1×
“Nonetheless, glargine is unlikely to cross the placenta (36), animal studies have not shown glargine to be embryotoxic (153), and women treated with insulin glargine during the first trimester have a similar rate of congenital malformations as women treated with insulin NPH (33, 154, 155).”
Magee, L. A., von Dadelszen, P., Bohun, C. M., Rey, E., El-Zibdeh, M., Stalker, S., Ross, S., Hewson, S., Logan, A. G., Ohlsson, A., et al. (2003) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(16)30579-5 · Cited by 77 · cited 1×
“Hypertension in a preconceptional woman increases the risk of adverse outcomes during pregnancy, especially her risk of developing preeclampsia (55).”
Simmons, D., Thompson, C. F., Conroy, C., & Scott, D. J. (2001) · Diabetes Care · doi:10.2337/diacare.24.12.2078 · Cited by 75 · cited 1×
“Compared with multiple daily doses of insulin, continuous sc insulin infusion used during pregnancy in women with overt diabetes provides comparable or better (166, 167)glycemiccontrolandpregnancyoutcomes(168,169) with no greater risk or possibly lower risk (170) of maternal hypoglycemia (171).”
Effect of a levonorgestrel intrauterine system on women with type 1 diabetes: a randomized trial
Rogovskaya, S., Rivera, R., Grimes, D. A., Chen, P.-L., Pierre-Louis, B., Prilepskaya, V., & Kulakov, V. (2005) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000156301.11939.56 · Cited by 75
Kousta, E., Efstathiadou, Z., Lawrence, N. J., Jeffs, J. A. R., Godsland, I. F., Barrett, S. C., Doré, C. J., Penny, A., Anyaoku, V., Millauer, B. A., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0058-6 · Cited by 74
Breastfeeding After Gestational Diabetes Pregnancy
Gunderson, E. P. (2007) · Diabetes Care · doi:10.2337/dc07-s210 · Cited by 71
Maternal glycemic criteria for insulin therapy in gestational diabetes mellitus.
Langer, O. (1998) · PubMed · Cited by 70
Pregnancy outcome in women with insulin-dependent diabetes mellitus complicated by nephropathy
Dunne, F. P. (1999) · QJM · doi:10.1093/qjmed/92.8.451 · Cited by 69 · cited 1×
“Mild preconceptional renal dysfunction manifesting only as microalbuminuria may worsen during pregnancy with greater amounts of proteinuria (47); however, the degree of worsening is typically both modest and reversible once pregnancy is completed so long as BP and blood glucose remain well controlled during the pregna…”
A risk-benefit assessment of the levonorgestrel-releasing intrauterine system
Sturridge, F., & Guillebaud, J. (1996) · Drug Safety · doi:10.2165/00002018-199615060-00006 · Cited by 69
Skouby, S. O., Kühl, C., Mølsted-Pedersen, L., Petersen, K., & Christensen, M. S. (1985) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(85)90460-0 · Cited by 67 · cited 1×
“Combined oral contraceptive use by women with a history of gestational diabetes does not increase the risk of later developing type 2 diabetes (220–223).”
Lapolla, A., Dalfr�, M. G., Masin, M., Bruttomesso, D., Piva, I., Crepaldi, C., Tortul, C., Dalla Barba, B., & Fedele, D. (2003) · Acta Diabetologica · doi:10.1007/s00592-003-0103-1 · Cited by 67 · cited 1×
“Compared with multiple daily doses of insulin, continuous sc insulin infusion used during pregnancy in women with overt diabetes provides comparable or better (166, 167)glycemiccontrolandpregnancyoutcomes(168,169) with no greater risk or possibly lower risk (170) of maternal hypoglycemia (171).”
(1985) · PubMed · Cited by 67
Prior gestational hyperglycemia: a long-term predictor of the metabolic syndrome
Bo, S., Monge, L., Macchetta, C., Menato, G., Pinach, S., Uberti, B., & Pagano, G. (2004) · Journal of Endocrinological Investigation · doi:10.1007/bf03347494 · Cited by 63
Garg, S. K. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510380055037 · Cited by 63
Durnwald, C. P., & Landon, M. B. (2008) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767050802022797 · Cited by 61 · cited 3×
“In most other respects, rapid-acting insulin and regular insulin are comparable during pregnancy (30, 158–162).”
Gestational diabetes and nutritional recommendations
Gunderson, E. P. (2004) · Current Diabetes Reports · doi:10.1007/s11892-004-0041-5 · Cited by 60
Survey of glargine use in 115 pregnant women with type 1 diabetes
Gallen, I. W., Jaap, A., Roland, J. M., & Chirayath, H. H. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02339.x · Cited by 60 · cited 10×
“When appropriate, insulin glargine may be replaced by insulin detemir or NPH insulin.”
Influential(1997) · PubMed · Cited by 59
Management of the Insulin-Dependent Diabetic During Labor and Delivery
Miodovnik, M., Mimouni, F., Tsang, R., Skillman, C., Siddiqi, T., Butler, J., & Holroyde, J. (1987) · American Journal of Perinatology · doi:10.1055/s-2007-999750 · Cited by 58
Glueck, C. J., Salehi, M., Sieve, L., & Wang, P. (2006) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2006.01.011 · Cited by 58 · cited 1×
“Metformin use by the breastfeeding woman vs formula feeding appears to have no adverse effects on infant growth, motor-social development, and intercurrent illness during the first 6 months of life (215).”
Lapolla, A., Dalfrà, M. G., Spezia, R., Anichini, R., Bonomo, M., Bruttomesso, D., Di Cianni, G., Franzetti, I., Galluzzo, A., Mello, G., et al. (2008) · Acta Diabetologica · doi:10.1007/s00592-008-0024-0 · Cited by 58
Insulin management during labour and delivery in mothers with diabetes
Lean, M. E. J., Pearson, D. W. M., & Sutherland, H. W. (1990) · Diabetic Medicine · doi:10.1111/j.1464-5491.1990.tb01352.x · Cited by 57
Kjos, S. L., Shoupe, D., Douyan, S., Friednman, R. L., Bernstein, G. S., Mestman, J. H., & Mishell, D. R. (1990) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(90)90757-x · Cited by 55
Self-citationNegrato, C. A., Rafacho, A., Negrato, G., Teixeira, M. F., Araújo, C. A. R., Vieira, L., Silva, C. A., Date, S. K., Demarchi, A. C., & Gomes, M. B. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.03.015 · Cited by 55 · cited 9×
“When appropriate, insulin glargine may be replaced by insulin detemir or NPH insulin.”
InfluentialGlyburide compared to insulin for the treatment of gestational diabetes mellitus: a cost analysis
Goetzl, L., & Wilkins, I. (2002) · Journal of Perinatology · doi:10.1038/sj.jp.7210759 · Cited by 54 · cited 1×
“Compared with insulin, glyburide may be more convenient, is less expensive (184), does not require intensive educational instruction at initiation of therapy, and is preferred by most patients (179, 183).”
ANDERSEN, O., HERTEL, J., SCHMØLKER, L., & KÜHL, C. (1985) · Acta Paediatrica · doi:10.1111/j.1651-2227.1985.tb10963.x · Cited by 54
Proposal for the reconsideration of the definition of gestational diabetes
Omori, Y., & Jovanovic, L. (2005) · Diabetes Care · doi:10.2337/diacare.28.10.2592 · Cited by 54
Bech, K., Høier-Madsen, M., Feldt-Rasmussen, U., Jensen, B. M., Mølsted-Pedersen, L., & Kühl, C. (1991) · Acta Endocrinologica · doi:10.1530/acta.0.1240534 · Cited by 54
Use of insulin glargine during pregnancy
PÖYHÖNEN‐ALHO, M., RÖNNEMAA, T., SALTEVO, J., EKBLAD, U., & KAAJA, R. J. (2007) · Acta Obstetricia et Gynecologica Scandinavica · doi:10.1080/00016340701515282 · Cited by 52
Buchbinder, A., Miodovnik, M., McElvy, S., Rosenn, B., Kranias, G., Khoury, J., & Siddiqi, T. A. (2000) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2000.108893 · Cited by 51 · cited 1×
“Rapid-acting insulin does not increase the risk of teratogenicity (30, 157, 158, 163–165).”
Use of insulin detemir in pregnancy: A report on 10 type 1 diabetic women
Lapolla, A., Di Cianni, G., Bruttomesso, D., Dalfrà, M. G., Fresa, R., Mello, G., Napoli, A., Romanelli, T., Sciacca, L., Stefanelli, G., et al. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02852.x · Cited by 51 · cited 1×
“Insulin detemir has not shown adverse maternal or neonatal effects (34, 144).”
Use of metformin in the treatment of polycystic ovary syndrome
Genazzani, A. D., Ricchieri, F., & Lanzoni, C. (2010) · Women's Health · doi:10.2217/whe.10.43 · Cited by 51
(2004) · PubMed · Cited by 51
Dicker, D., Feldberg, D., Samuel, N., Yeshaya, A., Karp, M., & Goldman, J. A. (1988) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(88)90245-1 · Cited by 50 · cited 10×
“Remarks The recommendation regarding measuring blood glucose at certain specific times after the start of a meal allows for consistency in testing across different cultural and per4238 Blumer et al Guideline on Diabetes and Pregnancy J Clin Endocrinol Metab, November 2013, 98(11):4227–4249”
Influential(2000) · PubMed · Cited by 49
Salvesen, K. Å., Vanky, E., & Carlsen, S. M. (2007) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.3965 · Cited by 48
Oral contraceptives in women with diabetes
Klein, B. E., Moss, S. E., & Klein, R. (1990) · Diabetes Care · doi:10.2337/diacare.13.8.895 · Cited by 47 · cited 1×
“Combined oral contraceptive use by women with type 1diabetesdoesnotaffecttheirglycemiccontrolorincrease their risk of end-organ injury (217–219).”
Glucose Targets in Pregnant Women With Diabetes: A Systematic Review and Meta-Analysis
Prutsky, G. J., Domecq, J. P., Wang, Z., Carranza Leon, B. G., Elraiyah, T., Nabhan, M., Sundaresh, V., Vella, A., Montori, V. M., & Murad, M. H. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2461 · Cited by 46
Self-citationUse of glargine in pregnant women with type 1 diabetes mellitus: a case-control study
IMBERGAMO, M., AMATO, M., SCIORTINO, G., GAMBINA, M., ACCIDENTI, M., CRISCIMANNA, A., GIORDANO, C., & GALLUZZO, A. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.08.013 · Cited by 46 · cited 1×
“Several retrospective cohort and case-control studies of pregnant women foundthatoverall,theoutcomewithinsulinglarginetreat-ment was no different from, or was superior to, NPH insulin (35, 145–149).”
Fraser, R. B., Ford, F. A., & Milner, R. D. G. (1983) · Diabetologia · doi:10.1007/bf00279936 · Cited by 46 · cited 1×
“Evidence There is no definitive evidence for the optimal proportion of carbohydrate in the diet of women with overt or gestational diabetes; values from 40% to 45% of energy intake (137) to 60% (if the carbohydrate is from complex sources) (138) have been recommended.”
Victor Fang, Y. M., Mackeen, D., Egan, J. F. X., & Zelop, C. M. (2009) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767050802638170 · Cited by 45
Bolton, S., Cleary, B., Walsh, J., Dempsey, E., & Turner, M. J. (2009) · European Journal of Pediatrics · doi:10.1007/s00431-008-0737-7 · Cited by 45
Ramos, G. A., Jacobson, G. F., Kirby, R. S., Ching, J. Y., & Field, D. R. (2007) · Journal of Perinatology · doi:10.1038/sj.jp.7211683 · Cited by 44
Predictors of infant birth weight in gestational diabetes
Snyder, J., Gray-Donald, K., & Koski, K. (1994) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/59.6.1409 · Cited by 43 · cited 2×
“Energy intake of approximately 2050 kcal in all BMI categories in women with gestational diabetes has been reported to limit maternal weight gain, maintain euglycemia, avoid ketonuria, and maintain an average birth weight of 3542 g (130).”
Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring
Weisberg, E., Fraser, I. S., Lacarra, M., Mishell, D. R., Alvarez, F., Brache, V, & Nash, H. A. (1999) · Contraception · doi:10.1016/s0010-7824(99)00035-9 · Cited by 43
Mathiesen, E. R., Damm, P., Jovanovic, L., McCance, D. R., Thyregod, C., Jensen, A. B., & Hod, M. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1213 · Cited by 43 · cited 1×
“Insulin detemir has not shown adverse maternal or neonatal effects (34, 144).”
Self-citationPetersen, K. R., Skouby, S. O., Sidelmann, J., Mølsted-Pedersen, L., & Jespersen, J. (1994) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(94)70041-9 · Cited by 38 · cited 1×
“The benefits of breastfeeding greatly outweigh the risks of these medications, if any (217).”
Research works printed but not linked: 8
- Langer, 2000, Level of glycemia and perinatal outcome in pregestational diabetes, J Matern Fetal Med, 9, 35, 10.1002/(SICI)1520-6661(200001/02)9:1<35::AID-MFM8>3.0.CO;2-6 · doi:10.1002/(sici)1520-6661(200001/02)9:1
- Confidential Enquiry into Maternal and Child Health (CEMACH), 2007, Diabetes in Pregnancy: Are We Providing the Best Care? Findings of a National Enquiry: England, Wales and Northern Ireland
- Leguizamon, 2000, Effect of medical therapy on progressive nephropathy: influence of pregnancy, diabetes and hypertension, J Matern Fetal Med, 9, 70, 10.1002/(SICI)1520-6661(200001/02)9:1<70::AID-MFM15>3.0.CO;2-# · doi:10.1002/(sici)1520-6661(200001/02)9:1
- Voelmle, 2007, Fetal outcomes and improved A1c values in pregnant women with type 1 diabetes using real-time continuous glucose sensors, Diabetes, 56, A117
- American Dietetic Association, 2002, Nutrition Practice Guidelines for Gestational Diabetes [CD-ROM]
- American Diabetes Association, 2000, American Diabetes Association: gestational diabetes (position statement), Diabetes Care, 23, S77
- Mimouni, 1987, Perinatal asphyxia in infants of diabetic mothers is associated with maternal vasculopathy and hyperglycaemia in labour, Neonat Epidemiol Follow-up, 400A
- Mayer-Davis, 2006, Breast-feeding and risk for childhood obesity: does maternal diabetes or obesity status matter?, Diabetes Care, 29, 2231, 10.2337/dc06-0974 · DOI · Paper page
Cited by
McIntyre, H. D., Catalano, P., Zhang, C., Desoye, G., Mathiesen, E. R., & Damm, P. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0098-8 · Cited by 1,850
A Clinical Update on Gestational Diabetes Mellitus
Sweeting, A., Wong, J., Murphy, H. R., & Ross, G. P. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac003 · Cited by 928
Epidemiology and management of gestational diabetes
Sweeting, A., Hannah, W., Backman, H., Catalano, P., Feghali, M., Herman, W. H., Hivert, M.-F., Immanuel, J., Meek, C., Oppermann, M. L., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00825-0 · Cited by 431
Duran, A., Sáenz, S., Torrejón, M. J., Bordiú, E., del Valle, L., Galindo, M., Perez, N., Herraiz, M. A., Izquierdo, N., Rubio, M. A., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0179 · Cited by 335
“8 mmol/L]), together with obstetric and pediatric monitoring as previously reported (14,15) and recommended by the Endocrine Society (7).”
BackgroundInfluentialBehboudi-Gandevani, S., Amiri, M., Bidhendi Yarandi, R., & Ramezani Tehrani, F. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-019-0406-1 · Cited by 321
Metadata
- Authors
- Blumer, I., Hadar, E., Hadden, D. R., Jovanovič, L., Mestman, J. H., Murad, M. H., & Yogev, Y.
- Affiliations
- Charles H. Best Diabetes Centre (I.B.), Whitby, Ontario, Canada L1M 1Z5
- Helen Schneider Hospital for Women (E.H., Y.Y.), Petach Tikva 49100, Israel
- Royal Victoria Hospital (GB)
- Sansum Diabetes Research Institute (US)
- University of Southern California (US)
- Mayo Clinic (US)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2013-11-01
- Volume
- 98
- Issue
- 11
- Pages
- 4227-4249
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC8998095
- OpenAlex
- W2109023860
- Semantic Scholar
- 2f63722c3f2b6b74d13e1f6171075ebf1a4f8cce
- Cited by
- 561
- References
- 265
- Citations by year
- 2026: 9 · 2025: 30 · 2024: 40 · 2023: 42 · 2022: 61 · 2021: 46 · 2020: 47 · 2019: 62 · 2018: 55 · 2017: 43 · 2016: 46 · 2015: 47 · 2014: 28 · 2013: 2
- FWCI
- 45.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- diabetes in pregnancy, gestational diabetes mellitus, type 1 diabetes, type 2 diabetes, preconception care, postpartum care, glycemic control, diabetes management in pregnancy
- MeSH terms
- Endocrinology, Female, Humans, Pregnancy, Pregnancy in Diabetics, Societies, Medical, Practice Guidelines as Topic, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.